3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
3
Vascular Diseases
2
Heart Diseases
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Neoplasms, Second Primary
1
Metabolic Diseases
1
Heart Failure
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Cancer Metastatic
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Cancer Therapy-related Cardiovascular Toxicity
1
Breast Neoplasms
1
Advanced Ovarian Cancer
1
Interventions
Trastuzumab
2
Ivabradine
2
Exercise
2
Echocardiography
2
Bisoprolol
2
salicylhydroxamic acid
1
sacubitril and valsartan sodium hydrate drug combination
1
mitoquinone
1
epicatechin gallate
1
dapagliflozin
1
candesartan
1
Trimetazidine
1
Therapeutics
1
Surveys and Questionnaires
1
Spironolactone
1
Silymarin
1
Secondary Prevention
1
Restraint, Physical
1
Ramipril
1
Radiotherapy
1
Perindopril
1
Neoadjuvant Therapy
1
Nebivolol
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Fluorouracil
1
Epirubicin
1
Docetaxel
1
Cyclophosphamide
1
Cisplatin
1
Carvedilol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Cardiotoxicity
×
Antineoplastic Agents
×
Clear all
NCT03882580
2023-04-24
NEOCARDIO
Groupe Hospitalier Pitie-Salpetriere
Unknown
5,000 enrolled